Vimarsana
Biggest News Aggregation in the World

Carl Regillo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Carl Regillo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Carl Regillo Today - Breaking & Trending Today

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration - Vimarsana News

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary...

Breye Therapeutics ApS developing oral ophthalmology drugs - Vimarsana News

Breye Therapeutics ApS developing oral ophthalmology drugs

Patients with diabetic retinopathy as a result of diabetes, could benefit from a small molecule drug.

EYP-1901 for Wet AMD Achieves Primary Endpoint in DAVIO 2 Trial - Vimarsana News

EYP-1901 for Wet AMD Achieves Primary Endpoint in DAVIO 2 Trial

Positive topline results from the phase 2 trial indicate EYP-1901 exhibited statistical non-inferiority in BCVA to aflibercept, with a favorable safety profile.

EyePoint Pharmaceuticals' stock soars 362% after company announces positive data from trial of wet AMD treatment - Vimarsana News

EyePoint Pharmaceuticals' stock soars 362% after company announces positive data from trial of wet AMD treatment

EyePoint's stock is on track for its biggest ever one-day percentage gain in heavy volume.

Adverum Biotechnologies Announces 3-Year Efficacy and - Vimarsana News

Adverum Biotechnologies Announces 3-Year Efficacy and

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of...